National Institute of Allergy and Infectious Diseases (NIAID): Lupus Erythematosus, Systemic trials

The registry lists 13 Lupus Erythematosus, Systemic studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 1 4Phase 2 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic LupusTerminatedNCT05306873Phase 2Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus ErythematosusCompletedNCT03618056Phase 1Results posted
• JBT-101 in Systemic Lupus Erythematosus (SLE)CompletedNCT03093402Phase 2Results posted
• Autologous Polyclonal Tregs for LupusTerminatedNCT02428309Phase 1Results posted
• Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)TerminatedNCT01946880Phase 2Results posted
• Vitamin D3 Treatment in Pediatric Systemic Lupus ErythematosusTerminatedNCT01709474Phase 2Results posted
• Abatacept and Cyclophosphamide Combination Therapy for Lupus NephritisCompletedNCT00774852Phase 2Results posted
• Vitamin D3 in Systemic Lupus ErythematosusCompletedNCT00710021Phase 2Results posted
• Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLEWithdrawnNCT01702038Phase 2
• Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)WithdrawnNCT00230035Phase 2
• Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)CompletedNCT00094380Phase 1/2
• Anti-CD20 in Systemic Lupus ErythematosusCompletedNCT00036491Phase 1/2